CA
NZ
UK
AU
IND
US
GRI Bio (NASDAQ:GRI) is a nano-cap clinical-stage biotechnology company staking its future on GRI-0621, an oral drug for idiopathic pulmonary fibrosis (IPF), a progressive and ultimately fatal scarring of the lungs. In June 2026 the company won FDA Orphan Drug Designation for the candidate, …
MetaVia Inc. (NASDAQ:MTVA) is a clinical-stage biotech betting that a twist on the blockbuster weight-loss formula can carve out room in a market dominated by Novo Nordisk and Eli Lilly. Its lead candidate, DA-1726, is a GLP-1/glucagon dual agonist aimed at obesity and metabolic …
Reviva Pharmaceuticals (OTCQB:RVPH) is a clinical-stage biotech chasing a big prize in psychiatry with a single lead drug, brilaroxazine, for schizophrenia. In 2026 the story turned harder. The FDA has asked for a second pivotal trial before it will consider approval, the company completed …
Evogene Ltd. (NASDAQ:EVGN), an Israeli computational biology company, is betting that generative AI can crack one of cardiology's harder problems: a cholesterol pill that rivals injectable blockbusters. At last closing, EVGN unveiled a collaboration with South Korea's ELEO Inc. to discover oral small-molecule PCSK9 …
IceCure Medical (NASDAQ:ICCM) is a small Israeli medical-device maker with an outsized ambition: replacing the surgical knife with extreme cold. Its ProSense system freezes and destroys tumours, and in October 2025 it won FDA clearance for early-stage breast cancer. At last closing the Society …
NEXGEL, Inc. (NASDAQ:NXGL), a micro-cap maker of ultra-gentle hydrogels, is attempting the boldest pivot in its history. In April 2026 the company closed a $13.3 million acquisition of Celularity's regenerative-biomaterials business, launching a surgical division it says could roughly triple annual revenue toward $35 …
Silexion Therapeutics (NASDAQ:SLXN) crossed a defining line at last closing, formally initiating its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center. For a company valued as a micro-cap, moving an experimental RNA-silencing therapy into a …
AIM ImmunoTech (NYSE American:AIM) is a clinical-stage immunotherapy company trying to convert decades of work on its lead drug, Ampligen, into a genuine value inflection. In 2026 the focus has narrowed sharply to pancreatic cancer, where AIM has completed enrollment in a mid-stage combination …
Azitra, Inc. (NYSE American:AZTR) is a synthetic-biology company that engineers skin bacteria into therapeutic and cosmetic proteins, and in July 2026 it delivered fresh laboratory data its investors hope can revive a battered share price. The company reported new ex vivo results for its …
Eloxx Pharmaceuticals (NASDAQ:ELOX) has spent 2026 rebuilding itself from the ground up. In a matter of weeks the rare-disease biotech executed a 1-for-11 reverse stock split, raised roughly $66 million in a public offering, and uplisted from the OTC Pink market to the Nasdaq …
Please wait processing your request...